

JUL 1 1 2007 W

D0273 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico

Type or print name

Signature

7-9-07

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1652

HUANG, ET AL.

EXAMINER: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: 08/26/2003

FOR: METHODS OF USING EphA2 FOR PREDICTING ACTIVITY OF

COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN

TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE

PATHWAYS IN BREAST CELLS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of an RCE application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

Statement Under 37 C.F.R. § 1.704(d)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application no more than 30 days prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: 7-8-07

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652

, , ,	i									
						Appro	oved for u	use through 07/31/20	PTO/SB/08A (8/03 006. OMB 0651-003	
0		 				U.S. Patent and Trader	nark Offic	ce; U.S. DEPARTME	ENT OF COMMERCI	
\Subs∰ute	for form 14	49/PTO		COMPLETE IF KNOWN						
10000000 1000 1000 1000 1000 1000 1000						Application Number		10/648,593		
	Mil-C	DMATION DISCLO	CHDE	•	Γ	Filing Date		08/26/2003		
FORMATION DISCLOSURE STATEMENT BY APPLICANT(S) (use as many sheets as necessary)			•		First Named Invento	r	FEI HUANG			
5 STATEMENT BY APPLICANTIS			(S)		Art Unit		1652			
	.6/	(use as many sheets as necessary	·)	(-)		Examiner Name		SWOPE, SHE	RIDAN	
T STREET N	1	of 2				Attorney Docket Nui	mber	D0273 NP		
U.S. PATENT DOC						•				
Examiner	Cite	Document Number	0.0.17	Publication (date	Name of Patentee		Pages, Columns, L	ines, Where Releva	
Initials	No.			MM-DD-YY	ΥΥ	Applicant of Cited Docu	ument	Passages or Rele	evant Figures Appear	
		· · · · · · · · · · · · · · · · · · ·								
								<u>, </u>		
	-									
				• • • •						
					·					
							·			
				•						
······ -								,		
		FO	REIGN	PATENT	r DC	CUMENTS				
Examiner Initials	Cite No.	Foreign Patent Document	Publica	ation Date D-YYYY	N	Name of Patentee or Where		s, Columns, Lines, Relevant Passages vant Figures Appear	Check box if Engli language translatio attached	
	AA	WO02/50306 A1	06/27	7/2002			51 110101	riguros Appear	U.lacried	
			-				<u> </u>			
			-				-			
			-				 			

Examiner
Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) (use as many sheets as necessary)

of 2

COMPLETE IF KNOWN Application Number 10/648,593 Filing Date 08/26/2003 First Named Inventor **FEI HUANG** Art Unit 1652 SWOPE, SHERIDAN **Examiner Name** Attorney Docket Number D0273 NP

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached			
	2AA	Hofmann, et al., "Relation between resistance of Philadelphia-chromosome-				
		positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor ST1571 and gene-expression profiles: a gene-expression study", The Lancet, Vol. 359, pp. 481-486 (2002)				
	2AB	Carles-Kinch, et al., "Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior", Cancer Res., Vol. 62, pp. 2840-2847 (2002)				
	2AC	NCBI Entrez Accession No. M59371 (gi:181943), Lindberg, et al., November 21, 1994				
			·			

Examiner	Date	
Signature	Considered	